AMPH
Amphastar Pharmaceuticals, Inc. NASDAQ Listed Jun 25, 2014$24.01
Mkt Cap $1.1B
52w Low $17.03
49.1% of range
52w High $31.26
50d MA $20.80
200d MA $25.11
P/E (TTM)
10.4x
EV/EBITDA
11.7x
P/B
1.3x
Debt/Equity
0.8x
ROE
22.0%
P/FCF
10.3x
RSI (14)
—
ATR (14)
—
Beta
0.91
50d MA
$20.80
200d MA
$25.11
Avg Volume
518.2K
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
11570 6th Street · Rancho Cucamonga, CA 91730 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.90 | 0.73 | -19.2% | 26.49 | -15.3% | -23.6% | -20.7% | -25.1% | -24.7% | -22.8% | — |
| Nov 6, 2025 | AMC | 0.77 | 0.93 | +20.8% | 24.23 | +7.9% | -0.8% | +7.8% | +12.1% | +14.9% | +8.8% | — |
| Aug 7, 2025 | AMC | 0.71 | 0.85 | +19.7% | 21.62 | +3.1% | +10.1% | +26.5% | +40.4% | +41.0% | +39.7% | — |
| May 7, 2025 | AMC | 0.66 | 0.74 | +12.1% | 24.43 | +0.7% | +0.9% | -1.3% | -0.4% | -2.3% | -4.6% | — |
| Feb 27, 2025 | AMC | 1.01 | 0.92 | -8.9% | 31.49 | -3.1% | -9.7% | -12.6% | -12.3% | -10.9% | -10.1% | — |
| Nov 6, 2024 | AMC | 0.99 | 0.96 | -3.0% | 53.40 | -10.2% | -13.7% | -9.5% | -9.0% | -10.7% | -14.8% | — |
| Aug 7, 2024 | AMC | 0.77 | 0.94 | +22.1% | 38.89 | +9.3% | +13.3% | +10.2% | +11.2% | +12.0% | +9.1% | — |
| May 8, 2024 | AMC | 0.96 | 1.04 | +8.3% | 42.21 | +7.9% | +0.5% | +0.0% | +0.4% | -2.2% | +0.5% | — |
| Feb 28, 2024 | AMC | 0.93 | 0.88 | -5.4% | 54.74 | -9.0% | -14.9% | -15.6% | -14.7% | -13.5% | -15.4% | — |
| Nov 8, 2023 | AMC | 0.69 | 1.15 | +66.7% | 45.42 | +5.7% | +15.4% | +15.7% | +17.9% | +24.0% | +26.6% | — |
| Aug 8, 2023 | AMC | 0.56 | 0.65 | +16.1% | 65.00 | -0.5% | -4.3% | -17.8% | -15.9% | -16.8% | -11.9% | — |
| May 9, 2023 | AMC | 0.48 | 0.62 | +29.2% | 36.44 | +3.4% | +13.0% | +14.4% | +14.2% | +14.6% | +17.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8 | Needham | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Apr 21 | Jefferies | Downgrade | Buy → Hold | $22 | $22.92 | $22.38 | -2.4% | -7.5% | -8.4% | -8.3% | -6.6% | -5.5% |
| Apr 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $20.58 | $20.68 | +0.5% | -0.9% | +1.4% | -1.0% | +3.8% | +3.9% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $26.49 | $22.44 | -15.3% | -23.6% | -20.7% | -25.1% | -24.7% | -22.8% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $26.49 | $22.44 | -15.3% | -23.6% | -20.7% | -25.1% | -24.7% | -22.8% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $24.23 | $26.15 | +7.9% | -0.8% | +7.8% | +12.1% | +14.9% | +8.8% |
| Oct 22 | Needham | Maintains | Buy → Buy | — | $24.26 | $24.14 | -0.5% | +1.1% | +1.9% | +1.1% | -0.9% | -0.3% |
| Aug 26 | BofA Securities | Maintains | Neutral → Neutral | — | $29.83 | $29.98 | +0.5% | +1.7% | +2.2% | +1.4% | +2.6% | +3.3% |
| Aug 12 | Needham | Upgrade | Hold → Buy | — | $27.36 | $28.18 | +3.0% | +10.9% | +11.4% | +10.4% | +9.0% | +8.8% |
| Aug 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $21.62 | $22.29 | +3.1% | +10.1% | +26.5% | +40.4% | +41.0% | +39.7% |
| May 12 | JP Morgan | Downgrade | Overweight → Neutral | — | $24.11 | $24.05 | -0.2% | +1.0% | -1.0% | -3.4% | +0.9% | +3.1% |
| May 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $24.43 | $24.59 | +0.7% | +0.9% | -1.3% | -0.4% | -2.3% | -4.6% |
| Apr 10 | Needham | Maintains | Hold → Hold | — | $25.23 | $24.99 | -1.0% | -6.8% | -4.2% | -3.2% | -6.9% | -8.9% |
| Mar 21 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.91 | $27.66 | -0.9% | +1.4% | +2.0% | +1.7% | +1.6% | +2.1% |
| Feb 4 | Piper Sandler | Downgrade | Overweight → Neutral | — | $33.39 | $32.42 | -2.9% | -0.6% | -1.8% | -1.8% | -3.1% | -3.5% |
| Aug 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $38.89 | $42.49 | +9.3% | +13.3% | +10.2% | +11.2% | +12.0% | +9.1% |
| Jun 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $40.03 | $40.20 | +0.4% | +0.8% | -0.1% | -3.8% | -6.1% | -3.7% |
| May 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $42.94 | $43.10 | +0.4% | +0.1% | +2.1% | +2.8% | +3.1% | +1.8% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.88 | $30.84 | -0.1% | -4.0% | -0.9% | -1.7% | +0.3% | +0.1% |
| Jul 29 | Capital One | Maintains | Overweight → Overweight | — | $37.27 | $37.62 | +0.9% | +0.3% | -0.8% | +0.3% | +0.1% | -0.8% |
| Mar 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $34.81 | $34.49 | -0.9% | -0.2% | -1.7% | -1.8% | -1.7% | +1.8% |
| Mar 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.47 | $30.00 | -1.5% | +12.6% | +14.2% | +14.0% | +12.3% | +12.2% |
| Jan 7 | Piper Sandler | Upgrade | Neutral → Overweight | — | $23.18 | $23.75 | +2.5% | +8.1% | +11.4% | +9.1% | +10.5% | +7.5% |
| Mar 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $18.44 | $18.27 | -0.9% | -2.4% | -2.9% | -2.0% | +0.3% | -2.4% |
| Jan 8 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $20.65 | $19.02 | -7.9% | -4.1% | -5.4% | -5.5% | -6.1% | -6.7% |
| Oct 5 | Northland Capital Markets | Upgrade | Market Perform → Outperform | — | $19.00 | $20.30 | +6.8% | +6.0% | +6.4% | +7.6% | +10.1% | +11.8% |
| Jul 9 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | $21.50 | $21.09 | -1.9% | -3.2% | -5.4% | -8.1% | -5.7% | -3.8% |
| May 11 | BMO Capital | Maintains | Market Perform → Market Perform | — | $18.79 | $18.80 | +0.1% | +2.1% | -1.4% | -1.5% | -4.3% | -3.2% |
| Mar 13 | Needham | Downgrade | Buy → Hold | — | $24.17 | $21.50 | -11.0% | -14.4% | -15.2% | -16.3% | -15.7% | -14.7% |
| Mar 13 | BMO Capital | Maintains | Market Perform → Market Perform | — | $19.58 | $19.72 | +0.7% | +3.9% | +3.4% | +1.1% | +1.7% | -0.1% |
| Nov 10 | BMO Capital | Maintains | Market Perform → Market Perform | — | $18.81 | $18.73 | -0.4% | -1.4% | -5.1% | -5.6% | -5.1% | -3.5% |
| Nov 9 | Raymond James | Downgrade | Outperform → Market Perform | — | $17.81 | $17.00 | -4.5% | +5.6% | +4.2% | +0.3% | -0.3% | +0.3% |
| Mar 14 | Raymond James | Downgrade | Strong Buy → Outperform | — | $14.74 | $13.96 | -5.3% | -17.2% | -8.9% | -9.4% | -6.7% | -3.2% |
| Aug 9 | Jefferies | Maintains | Buy → Buy | — | $16.02 | $17.80 | +11.1% | +12.0% | +13.4% | +16.5% | +13.0% | +14.7% |
| Jun 29 | BMO Capital | Maintains | Market Perform → Perform | — | $16.63 | $16.59 | -0.2% | -3.3% | -3.1% | -2.1% | -1.8% | +0.4% |
| Feb 19 | Wells Fargo | Maintains | Outperform → Outperform | — | $11.18 | $11.18 | +0.0% | +1.6% | +2.5% | -0.6% | +0.2% | -0.4% |
| Jan 19 | Jefferies | Maintains | Buy → Buy | — | $12.29 | $12.35 | +0.5% | -2.2% | +1.9% | -0.2% | -0.3% | -1.4% |
| Nov 13 | Jefferies | Maintains | Buy → Buy | — | $12.26 | $12.14 | -1.0% | +13.4% | +12.6% | +15.7% | +20.3% | +17.4% |
| Jun 3 | Raymond James | Downgrade | Strong Buy → Buy | — | $15.79 | $16.04 | +1.6% | +4.4% | +4.3% | +4.2% | +4.9% | +2.8% |
| Mar 25 | Jefferies | Maintains | Buy → Buy | — | $15.33 | $15.50 | +1.1% | -5.9% | -2.5% | +0.7% | -2.4% | -2.4% |
| Aug 13 | Jefferies | Maintains | Buy → Buy | — | $10.20 | $9.80 | -3.9% | -0.5% | -0.7% | -0.5% | -1.8% | -1.9% |
| Jul 21 | PiperJaffray | Maintains | Overweight → Overweight | — | $9.55 | $9.70 | +1.6% | -2.1% | -0.5% | -4.3% | -3.5% | -6.0% |
| Jul 21 | Needham | Maintains | Buy → Buy | — | $9.55 | $9.70 | +1.6% | -2.1% | -0.5% | -4.3% | -3.5% | -6.0% |
| Jul 21 | Jefferies | Maintains | Buy → Buy | — | $9.55 | $9.70 | +1.6% | -2.1% | -0.5% | -4.3% | -3.5% | -6.0% |
| Jul 21 | BMO Capital | Maintains | Outperform → Outperform | — | $9.55 | $9.70 | +1.6% | -2.1% | -0.5% | -4.3% | -3.5% | -6.0% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
AMPH filed a generic 8-K with minimal substantive disclosure, suggesting either a routine procedural matter or incomplete filing that provides no clear fundamental catalyst for the stock.
Mar 16
8-K
Amphastar Pharmaceuticals, Inc. -- 8-K Filing
Amphastar Pharmaceuticals appointed a new executive with competitive compensation including $590,000 base salary, performance bonuses up to 53% of base, and equity incentives, signaling management continuity and potential strategic leadership changes.
Mar 6
8-K · 1.01
!! High
Amphastar Pharmaceuticals, Inc. -- 8-K 1.01: Supply Agreement
Amphastar Pharmaceuticals entered a supply agreement with Nanjing Letop Biotechnology, expanding its pharmaceutical sourcing capabilities and potentially strengthening its product pipeline.
Mar 6
8-K
Amphastar Pharmaceuticals, Inc. -- 8-K Filing
Amphastar Pharmaceuticals reported fourth quarter and full-year 2025 financial results, demonstrating operational performance across its generic and proprietary injectable, inhalation, and intranasal product portfolio.
Feb 26
Data updated apr 24, 2026 5:52pm
· Source: massive.com